Human study PLS-00221

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

Other design · 20 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degenerationregistry entry · NCT02314299 (COMPLETED, no results posted, planned enrollment 20)

Design and participants

Design: Other design
Population: Subjects with diabetic macular edema or non-exudative intermediate age-related macular degeneration
Conditions: Diabetic Macular Edema, Age-related Macular Degeneration
Planned enrollment (registry): 20
Enrolled: 20
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

MTP-131 topical ophthalmic solution (intervention) · elamipretide · MTP-131 (elamipretide) given as a topical ophthalmic solution. This is the only intervention listed; no comparator is listed in the record. · topical ophthalmic · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

abstract only: Only a registry entry is available. It has no posted results, abstract or publication, so no outcomes or findings can be appraised.
selective reporting: The study is listed as completed but has_results is false, so results have not been made available.
no control group: The registry lists only the MTP-131 intervention, with no comparator or placebo arm, and randomization is not described.
small or imprecise: Actual enrollment was only 20 participants across two different eye conditions.
inappropriate population: The participants had retinal disease (DME, AMD), unlike the Barth syndrome or mitochondrial myopathy claims, and received a topical eye formulation.
other: Only a registry record is available with no posted results, so design details, allocation, outcomes and safety findings cannot be appraised.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves function in Barth syndrome: not eligible (wrong population) for “Muscle strength, exercise capacity and fatigue”
Improves exercise capacity in primary mitochondrial myopathy: not eligible (wrong population) for “Six-minute walk distance and fatigue”
Is safe for human administration: not eligible (insufficient data) for “Adverse events, including injection-site reactions, and discontinuations”

Where each value comes from

arms: NCT NCT02314299, title (study title naming MTP-131 topical ophthalmic solution) · extracted by AI (automated, not verified by a person)
design: NCT NCT02314299, registry (phases, study_type, interventions fields) · extracted by AI (automated, not verified by a person)
limitations: NCT NCT02314299, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
participants: NCT NCT02314299, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
population: NCT NCT02314299, registry (conditions field and study title) · extracted by AI (automated, not verified by a person)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).